NCT03010072View on ClinicalTrials.gov

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

May 10, 2019

Conditions
Endstage Renal Disease
Interventions
DRUG

low-dose sucroferric oxyhydroxide

250 mg suroferric oxyhydroxide

DRUG

high-dose sucroferric oxyhydroxide

2000 mg suroferric oxyhydroxide

Trial Locations (1)

4020

Ordensklinikum Linz GmbH Elisabethinen, Linz

All Listed Sponsors
collaborator

Vifor Fresenius Medical Care Renal Pharma

INDUSTRY

lead

Prim. Priv. Doz. Dr. Daniel Cejka

OTHER

NCT03010072 - The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum | Biotech Hunter | Biotech Hunter